The prospective, multicenter ASTuTE implementation study included 786 men receiving radiotherapy for intermediate-risk prostate cancer.
2
After receiving the test results, 176 of 230 patients initially recommended short-term androgen deprivation therapy (ST-ADT) decided against it.
3
Testing supported newly recommending ST-ADT for 21 patients, while planned use across the cohort fell by a net 20.7%.
4
The test combines clinical factors with biopsy-slide information to estimate 10-year distant metastasis risk and predict benefit from adding 4 to 6 months of ST-ADT.
5
The interim findings show changes in treatment decisions, but longer-term outcomes are needed to determine effects on quality of life and disease control.
